



Five Prime Therapeutics, Inc.  
Investor Relations Department  
Two Corporate Dr, Suite 200  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: FPRX <sup>1</sup>

Last Trade:	29.85
Trade Time:	4:00 PM ET Friday, July 21, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	26.65 - 60.98
Volume	N/A
Market Cap. (\$M)	859.382
Shares Out (M)	28.790

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Monday, July 17, 2017*

[Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development](#)

*Wednesday, June 21, 2017*

[Five Prime Therapeutics Announces Lewis T. "Rusty" Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018](#)

*Monday, June 5, 2017*

[Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference](#)

*Sunday, June 4, 2017*

[Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis \(PVNS\) at 2017 ASCO Annual Meeting](#)

*Saturday, June 3, 2017*

[Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Friday, February 24, 2017*  
[Annual Report \(10-K\)](#)

*Friday, March 31, 2017*  
[Definitive Proxy Statement](#)

*Friday, May 5, 2017*  
[Quarterly Report \(10-Q\)](#)

*Friday, November 4, 2016*  
[Quarterly Report \(10-Q\)](#)

*Friday, August 5, 2016*  
[Quarterly Report \(10-Q\)](#)